Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Allegro Diagnostics has entered a license agreement with Boston University and the University of Utah Foundation for intellectual property of its molecular testing platform - BronchoGen genomic test.
Subscribe to our email newsletter
Allegro has devised a molecular testing platform that makes use of a genomic biomarker to detect early signs of lung cancer in current and former smokers.
BronchoGen genomic test is used in combination with standard bronchoscopy for the early diagnosis of lung cancer.
Allegro Diagnostics president and CEO Mike Webb said the licensing agreement with Boston University and theUniversity of Utah Foundation helps them to achieve that goal by supporting their advancement of this platform,including the planned commercial launch of BronchoGen in the first half of 2012.